Semler Scientific Inc
Semler Scientific, Inc. is the second U.S. public company to adopt Bitcoin as its primary treasury reserve asset and is a leader in medical devices and software to combat chronic diseases. By using proceeds from equity and debt financings, as well as cash flows from operations, Semler Scientific intends to strategically accumulate Bitcoin. In addition, through its healthcare businesses, Semler Scientific and its wholly-owned subsidiary, CardioVanta, Inc. develop and market products and services for early detection and monitoring of chronic diseases. Semler Scientific's flagship product, QuantaFlo, which is patented and cleared by the U.S. Food and Drug Administration (FDA), provides rapid point-of-care testing to measure arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of peripheral arterial disease.
Current Price
$20.33
+0.00%GoodMoat Value
$128.87
533.9% undervaluedSemler Scientific Inc (SMLR) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Semler Scientific Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $36.96M. Gross profit (TTM) is $33.54M. EBITDA is $66.15M. Earnings per share (EPS) is $5.13. The P/E ratio is 6.23. Market capitalization is $300.98M.
Free cash flow (FCF) is $24.63M. FCF growth rate is 36.22%. EPS growth CAGR is 41.88%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY18 to FY24. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Semler Scientific Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
